Immunome stock (US45254C1062): Institutional investors see $269M market cap drop

Immunome shares closed at $22.20 on May 13, 2026, down 2.16% amid a $269 million market cap decline for institutional holders last week, per MarketBeat data.

Immunome stock experienced a 2.16% decline, closing at $22.20 on May 13, 2026, on Nasdaq, according to MarketBeat as of 05/13/2026. Institutional investors saw a US$269 million decrease in market cap last week, though long-term gains have benefited them. The biotech firm, focused on cancer therapies, also advanced its Phase 1 trial for 177Lu-IM-3050 in solid malignancies.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Immunome, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology, autoimmune therapies
• Key revenue drivers: Clinical-stage pipeline
• Home exchange/listing venue: Nasdaq (IMNM)
• Trading currency: USD

Immunome: core business model

Immunome is a clinical-stage biotechnology company developing targeted cancer therapies using its proprietary Discovery Engine platform. The platform leverages human memory B cell screening to identify novel antibodies for oncology and autoimmune diseases. This approach aims to create therapeutics with high specificity and reduced toxicity. The company, listed on Nasdaq under IMNM, focuses on radiopharmaceuticals and antibody-drug conjugates for solid tumors.

Main revenue and product drivers for Immunome

Immunome's lead candidate, 177Lu-IM-3050, is in a Phase 1 trial for solid malignancies, evaluating safety and efficacy as noted on WithPower as of 2026. The trial targets patients 18+ with no placebo arm, sponsored by Immunome. Pipeline advancement remains key, with institutional ownership at 44.6% and insiders holding 7.2%, per MarketBeat competitor analysis.

Industry trends and competitive position

The biotech sector sees rising interest in radiopharmaceuticals for cancer, with Immunome competing against firms like ABVX and PRAX in MED - BIOMED/GENE. Institutional focus highlights long-term potential despite short-term volatility. Immunome's Nasdaq listing provides US investors exposure to innovative oncology plays amid growing demand for precision therapies.

Why Immunome matters for US investors

Immunome offers US investors access to next-gen cancer treatments via Nasdaq trading. Its pipeline targets high unmet needs in solid tumors, aligning with US healthcare spending trends. Extended trading showed a 0.75% uptick to $22.37 as of May 14 morning, reflecting resilience.

Conclusion

Immunome stock faced a recent dip with institutional market cap losses, yet its clinical progress in oncology sustains interest. Long-term institutional gains underscore pipeline value. US investors track Nasdaq-listed biotechs like IMNM for innovation exposure amid sector volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.